Oestrogen receptor-positive tumours and tumours in the basal-like/negative subgroup seem to derive benefit from high-dose chemotherapy, whereas a trend is seen that tumours with HER2 amplification might benefit more from conventional chemotherapy. Here, ERBB2 is linked to neoplasm.